Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,315 INR | +2.43% | -1.61% | +18.07% |
03-29 | Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director | CI |
03-29 | Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With an expected P/E ratio at 53.25 and 34.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.54 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.07% | 3.99B | C+ | ||
+30.38% | 684B | C+ | ||
+26.51% | 568B | B | ||
-4.36% | 361B | C+ | ||
+19.30% | 329B | B- | ||
+3.73% | 284B | C+ | ||
+16.70% | 240B | B+ | ||
+8.78% | 208B | B- | ||
-7.93% | 200B | A+ | ||
+7.68% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IPCALAB Stock
- IPCALAB Stock
- Ratings Ipca Laboratories Limited